Table 2 Comparison of patients with P. aeruginosa without mutation vs with mutation Bacteriological data

Prior ICU colonization no/yes

98 (82.4%) / 21 (17.6%)

27 (79.4%) / 7 (20.6%)

0.801

Infection with P. aeruginosa no/yes

46 (38.7%) / 73 (61.3%)

4 (11.8%) / 30 (88.2%)

0.003*

Other infections no/yes

36 (30.3%) / 83 (69.7%)

5 (14.7%) / 29 (85.3%)

0.081

Initial resistance no/yes

23 (19.3%) / 96 (80.7%)

15 (44.1%) / 19 (55.9%)

0.006*

 1= impermeability

1 (0.8%)

2 (5.9%)

0.005*

 3= Penicillinase and/or efflux

45 (37.8%)

11 (32.4%)

 4= AmpC over-production

10 (8.4%)

0 (0%)

 5= impermeability +/- Over-production of efflux

9 (7.6%)

4 (11.8%)

 6= 4+5

25 (21%)

1 (2.9%)

Fluoroquinolone resistance no/yes

74 (62.2%) / 45 (37.8%)

25 (73.5%) / 9 (26.5%)

0.309

Aminoglycoside resistance no/yes

94 (79%) / 25 (21%)

34 (100%) / 0 (0%)

0.001*

 P. aeruginosa ATB 1 adapted (n=97) no/yes

10 (14.9%) / 57 (85.1%)

2 (6.7%) / 28 (93.3%)

0.332

 P. aeruginosa ATB 2 adapted (n=66) no/yes

2 (5%) / 38 (95%)

0 (0%) / 26 (100%)

0.515

 P. aeruginosa ATB 3 adapted (n=28) no/yes

0 (0%) / 13 (100%)

2 (13.3%) / 13 (86.7%)

0.484

 Tazocillin after P. aeruginosa no/yes

94 (79%) / 25 (21%)

23 (67.6%) / 11 (32.4%)

0.176

 Ceftazidime after P. aeruginosa no/yes

95 (79.8%) / 24 (20.2%)

19 (55.9%) / 15 (44.1%)

0.007*

 Cefepime after P. aeruginosa no/yes

101 (84.9%) / 18 (15.1%)

30 (88.2%) /4 (11.8%)

0.785

 Meropenem after P. aeruginosa no/yes

79 (66.4%) / 40 (33.6%)

15 (44.1%) / 19 (55.9%)

0.027*

 Fluoroquinolone after P. aeruginosa no/yes

115 (96.6%) / 4 (3.4%)

34 (100%) / 0 (0%)

0.576

 Aminoglycosides after P. aeruginosa no/yes

57 (47.9%) / 62 (52.1%)

8 (23.5%) / 26 (76.5%)

0.017*